Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (371-380 of 953) with videos related to

Pageof 96
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 27, 2014
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinicFlora H Duits, Niels D Prins, Afina W Lemstra, et al.
Alzheimer'S Research & Therapy|July 15, 2022
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profilesKirsten E J Wesenhagen, Betty M Tijms, Lynn Boonkamp, et al.
Neurobiology of Aging|November 8, 2017
Gray matter network measures are associated with cognitive decline in mild cognitive impairmentEllen Dicks, Betty M Tijms, Mara Ten Kate, et al.
Journal of Parkinson'S Disease|July 25, 2018
Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's DiseaseMeltem Ciliz, Jennifer Sartor, Tobias Lindig, et al.
Frontiers in Aging Neuroscience|May 11, 2017
MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive ImpairmentMaria E López, Marjolein M A Engels, Elisabeth C W van Straaten, et al.
Journal of Alzheimer'S Disease : JAD|October 30, 2014
Serum leptin is not altered nor related to cognitive decline in Alzheimer's diseaseCharlotte E Teunissen, Wiesje M van der Flier, Philip Scheltens, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2024
The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidencePaul Aisen, Randall J Bateman, Damian Crowther, et al.
Journal of Alzheimer'S Disease : JAD|February 19, 2010
Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjectsNicolaas A Verwey, Maartje I Kester, Wiesje M van der Flier, et al.
JMIR Research Protocols|March 22, 2018
Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over TrialJolien Fleur Leijenaar, Geert Jan Groeneveld, Wiesje Maria van der Flier, et al.
Trials|September 24, 2013
The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trialKarlijn J Joling, Judith E Bosmans, Harm W J van Marwijk, et al.
Pageof 96

Showing results (371-380 of 953) with videos related to

Sort By:
Pageof 96
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 27, 2014
Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinicFlora H Duits, Niels D Prins, Afina W Lemstra, et al.
Alzheimer'S Research & Therapy|July 15, 2022
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profilesKirsten E J Wesenhagen, Betty M Tijms, Lynn Boonkamp, et al.
Neurobiology of Aging|November 8, 2017
Gray matter network measures are associated with cognitive decline in mild cognitive impairmentEllen Dicks, Betty M Tijms, Mara Ten Kate, et al.
Journal of Parkinson'S Disease|July 25, 2018
Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's DiseaseMeltem Ciliz, Jennifer Sartor, Tobias Lindig, et al.
Frontiers in Aging Neuroscience|May 11, 2017
MEG Beamformer-Based Reconstructions of Functional Networks in Mild Cognitive ImpairmentMaria E López, Marjolein M A Engels, Elisabeth C W van Straaten, et al.
Journal of Alzheimer'S Disease : JAD|October 30, 2014
Serum leptin is not altered nor related to cognitive decline in Alzheimer's diseaseCharlotte E Teunissen, Wiesje M van der Flier, Philip Scheltens, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2024
The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidencePaul Aisen, Randall J Bateman, Damian Crowther, et al.
Journal of Alzheimer'S Disease : JAD|February 19, 2010
Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjectsNicolaas A Verwey, Maartje I Kester, Wiesje M van der Flier, et al.
JMIR Research Protocols|March 22, 2018
Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over TrialJolien Fleur Leijenaar, Geert Jan Groeneveld, Wiesje Maria van der Flier, et al.
Trials|September 24, 2013
The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trialKarlijn J Joling, Judith E Bosmans, Harm W J van Marwijk, et al.
Pageof 96